Altogether, these in vivo results also indicate that HNSCC stem-like cells are relatively malignant and that this malignancy can be overcome by inhibiting the ERK1/2-Nanog pathway. This evidence concerns the gene MAPK3 and head and neck squamous cell carcinoma.